Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jul:147:103265.
doi: 10.1016/j.jaut.2024.103265. Epub 2024 Jun 4.

The HyperPed-COVID international registry: Impact of age of onset, disease presentation and geographical distribution on the final outcome of MIS-C

Roberta Caorsi  1 Alessandro Consolaro  2 Camilla Speziani  1 Betul Sozeri  3 Kadir Ulu  3 Enrique Faugier-Fuentes  4 Hector Menchaca-Aguayo  4 Seza Ozen  5 Seher Sener  5 Shahana Akhter Rahman  6 Mohammad Imnul Islam  6 Filomeen Haerynck  7 Gabriele Simonini  8 Mariel Viviana Mastri  9 Tadej Avcin  10 Saša Sršen  11 Taciana de Albuquerque Pedrosa Fernandes  12 Valda Stanevicha  13 Jelena Vojinovic  14 Ali Sobh  15 Sarka Fingerhutova  16 Lenka Minxova  17 Alenka Gagro  18 Adriana Rodrigues Fonseca  19 Devang Pandya  20 Boriana Varbanova  21 Judith Sánchez-Manubens  22 Margarita Ganeva  23 Davide Montin  24 Oksana Boyarchuk  25 Andrea Minghini  1 Claudia Bracaglia  26 Paul Brogan  27 Fabio Candotti  28 Marco Cattalini  29 Isabelle Meyts  30 Francesca Minoia  31 Andrea Taddio  32 Carine Wouters  33 Fabrizio De Benedetti  26 Francesca Bovis  34 Angelo Ravelli  35 Nicolino Ruperto  36 Marco Gattorno  37 HyperPED-COVID study groupERN-RITA (European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases)PReS (Pediatric Rheumatology European Society)ESID (European Society for Immunodeficiencies)ISSAID (International Society of Systemic Auto-Inflammatory Diseases) and the**Paediatric Rheumatology International Trials Organisation (PRINTO)Yelda Bilginer  38 Kamrul Laila  39 Mohammed Mahbubul Islam  39 Bram Meertens  40 Levi Hoste  40 Joke Dehoorne  40 Petra Schelstraete  40 Kristof Vandekerckhove  40 Jef Willems  40 Inge Matthijs  41 Giovanni Filocamo E Gisella Beatrice Beretta  42 Claudia Saad Magalhaes  43 Oksana Chubata  44 Francesca Ricci  45 Antonija Vukovic  46 Katya Temelkova  47 Mojca Zajc Avramovic  48 Nina Emersic  48 Masa Bizjak  48 Tina Vesel  48 Marta Felix Rodrigues  49 Rozana Gasparello de Almeida  49 Kristine Lukjanovica  50 Marwa H Elnagdy  51 Ahmed Soliman  52 Eva Terifajova  53 Ivana Brejchova  54 Martin Magner  55 Charlotte Myrup  56 Olga Vougiouka  57 Marija Jelusic  58 Francesco La Torre  59 Donato Rigante  60 Maria Cristina Maggio  61 Lucio Verdoni  62 Nadina Rubio-Perez  63 Gabriel Vega Cornejo  64 Ana Victoria Villarreal Trevino  63 Iva Brito  65 Filipa Oliveira-Ramos  66 Ekaterina Alexeeva  67 Vyacheslav Chasnyk  68 Thaschawee Arkachaisri  69 Yaryna Boyko  70 Yulia Vyzhga  71 Svitlana Samsonenko  72
Affiliations
Multicenter Study

The HyperPed-COVID international registry: Impact of age of onset, disease presentation and geographical distribution on the final outcome of MIS-C

Roberta Caorsi et al. J Autoimmun. 2024 Jul.

Abstract

Objectives: The aim of the study was to establish an international multicenter registry to collect data on patients with Multisystem Inflammatory Syndrome in Children (MIS-C), in order to highlight a relationship between clinical presentation, age of onset and geographical distribution on the clinical outcome.

Study design: Multicenter retrospective study involving different international societies for rare immunological disorders.1009 patients diagnosed with MIS-C between March and September 2022, from 48 centers and 22 countries were collected. Five age groups (<1, 1-4, 5-11, 12-16, >16 years) and four geographic macro-areas, Western Europe, Central-Eastern Europe, Latin America, Asian-African resource-limited countries (LRC), were identified.

Results: Time to referral was significantly higher in LRC. Intensive anti-inflammatory treatment, including biologics, respiratory support and mechanic ventilation were more frequently used in older children and in European countries. The mortality rate was higher in very young children (<1 year), in older patients (>16 years of age) and in LRC. Multivariate analysis identified the residence in LRC, presence of severe cardiac involvement, renal hypertension, lymphopenia and non-use of heparin prophylaxis, as the factors most strongly associated with unfavorable outcomes.

Conclusions: The stratification of patients by age and geographic macro-area provided insights into the clinical presentation, treatment and outcome of MIS-C. The mortality and sequelae rates exhibited a correlation with the age and geographical areas. Patients admitted and treated in LRC displayed more severe outcomes, possibly due to delays in hospital admission and limited access to biologic drugs and to intensive care facilities.

Keywords: Disease outcome; Limited resources countries; MIS-C; Registry; bDMARDs.

PubMed Disclaimer

References

Publication types

Supplementary concepts

LinkOut - more resources